Crinetics Pharmaceuticals
CRNX
83 hedge funds and large institutions have $661M invested in Crinetics Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 47 increasing their positions, 13 reducing their positions, and 9 closing their positions.
262% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 13
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
42% more capital invested
Capital invested by funds: $465M → $661M (+$196M)
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
4% more funds holding
Funds holding: 80 → 83 (+3)
5.91% less ownership
Funds ownership: 93.35% → 87.44% (-5.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$12.4M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$10.7M |
| 3 |
BlackRock
New York
|
+$7.5M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$6.15M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
-$21.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.96M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$8.11M |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$4.15M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$3.69M |
CRNX Hedge Fund Activity: Q2 2021 in Review
83 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q2 2021, worth a combined $661M — up 42% from $465M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CRNX positions and 9 closed out — a net gain of 3 holders — while 47 added to existing stakes and 13 trimmed.
The largest buyer was Driehaus Capital Management, adding an estimated $12.4M. The largest seller was Versant Venture Management, cutting an estimated $21.3M.
- 83 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q2 2021, up from 80 in Q1 2021.
- Funds reported $661M of Crinetics Pharmaceuticals stock for Q2 2021, up 42% quarter-over-quarter.
- 12 funds opened new Crinetics Pharmaceuticals positions in Q2 2021 and 9 closed out, a net change of +3 holders.
- The largest Crinetics Pharmaceuticals buyer in Q2 2021 was Driehaus Capital Management, an estimated $12.4M added.
- The largest Crinetics Pharmaceuticals seller in Q2 2021 was Versant Venture Management, an estimated $21.3M sold.
Based on aggregated 13F filings for Q2 2021.